Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Insists US Biosimilars Market Is Working Well

Executive Summary

Amgen insists that the initial response to the trastuzumab and bevacizumab biosimilars it has launched in the US, as well as the pressure it is feeling from competition to its Neulasta pegfilgrastim original, show that the US biosimilars market is functioning well. Therefore, the firm feels, structural interventions are unnecessary.

You may also be interested in...

Biosimilars Viability Debate Boils Up Between US Experts

The latest salvo has been fired in a fierce debate between US healthcare experts on whether US policymakers and payers should give up on biosimilars in favor of price controls on original biologics.

Coherus Fends Off Amgen’s Pegfilgrastim Purification Patent Case

Coherus’ manufacturing process for its Udenyca pegfilgrastim biosimilar does not infringe a US purification patent held by Amgen, the US Court of Appeals has confirmed.

Legality Of J&J's Remicade Contracting Depends On Share Of Biosimilar Market Foreclosed, Court Rules

Court denies J&J's motion to dismiss Pfizer's antitrust suit, saying discovery will reveal whether Pfizer has offered more competitive pricing for its Inflectra biosimilar and if there are alternative causes for Pfizer's inability to gain market share.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts